Abstract
In this editorial, the generalizability of trial results to the geriatric population is discussed. Specifically, the results from a recent observational study are compared with results from the SHARP trial, and recommendations are made for bridging the gap between efficacy and effectiveness in clinical research, particularly with regard to older patients.